Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Etonogestrel
Drug ID BADD_D00852
Description Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel.[A37184] The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001.[L5692]
Indications and Usage For use as a female contraceptive (depot).
Marketing Status Prescription; Discontinued
ATC Code G03AC08
DrugBank ID DB00294
KEGG ID D04104
MeSH ID C044815
PubChem ID 6917715
TTD Drug ID D02KIU
NDC Product Code 65089-0053; 64918-1500; 60870-0475; 78206-145; 71161-147; 63190-0480; 63190-0260; 45541-1192; 64918-1906
Synonyms etonogestrel | 13-ethyl-17-hydroxy-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one | 3-oxodesogestrel | 3-ketodesogestrel | 3-oxo desogestrel | 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-, (17-alpha)- | 3-keto-desogestrel | ORG-3236 | Implanon | nexplanon
Chemical Information
Molecular Formula C22H28O2
CAS Registry Number 54048-10-1
SMILES CCC12CC(=C)C3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Influenza like illness08.01.03.0100.007837%
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Insomnia19.02.01.002; 17.15.03.002--
Intentional self-injury12.01.08.036; 19.12.01.002--Not Available
Intracranial pressure increased17.07.02.002--Not Available
Irritability19.04.02.013; 08.01.03.0110.017323%
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Joint dislocation15.01.07.002; 12.04.02.0070.000825%Not Available
Joint swelling15.01.02.004--Not Available
Keloid scar23.01.03.0020.004537%Not Available
Kidney infection11.01.14.006; 20.01.09.004--
Laboratory test abnormal13.18.01.001--Not Available
Laceration23.03.11.004; 12.01.06.0060.004537%Not Available
Lethargy08.01.01.008; 19.04.04.004; 17.02.04.003--
Leukopenia01.02.02.001--Not Available
Libido decreased21.03.02.005; 19.08.03.0010.007012%
Libido increased21.03.02.007; 19.08.03.0020.000825%
Ligament sprain12.01.07.008; 15.07.02.0040.001650%Not Available
Lip swelling23.04.01.007; 10.01.05.005; 07.05.04.005--Not Available
Liver disorder09.01.08.001--Not Available
Local swelling08.01.03.0130.005362%Not Available
Localised infection11.01.08.0060.002475%Not Available
Loss of consciousness17.02.04.004--Not Available
Loss of libido19.08.03.0030.004537%Not Available
Lymphadenopathy01.09.01.002--Not Available
Macule23.03.03.0370.000825%Not Available
Malaise08.01.01.003--
Malignant melanoma23.08.01.001; 16.03.01.001--Not Available
Mass08.03.05.0030.003712%Not Available
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 19 Pages